Presenter: Stanley Cohen, Metroplex Clinical Research Center, Dallas, Texas, USA.
Wednesday 12 June: 16:15–17:45 (Abstract OP0025)
In this phase II trial, patients with moderate-to-severe active rheumatoid arthritis and an inadequate response to methotrexate were randomly assigned to receive fenebrutinib (GDC-0853) at various doses, adalimumab, or placebo, while those with an inadequate response to tumor necrosis factor inhibitors were randomly assigned to fenebrutinib or placebo, all given in addition to background methotrexate. The two primary outcomes are ACR50 response rate at week 12 and the emergence of adverse events.